Studying Psychiatric and Cognitive Traits in Velocardiofacial, Williams, and Fragile X Syndromes Using Treatment with Methylphenidate, Fluoxetine, and Risperidone

What this Trial Is About

This research investigates the psychiatric and cognitive characteristics in people with Velocardiofacial Syndrome VCFS, Williams Syndrome WS, and Fragile X Syndrome. It also explores connections between these conditions and developmental or molecular factors. The study is a phase 4 clinical trial aimed at better understanding these complex syndromes and their treatment responses. Participants will undergo evaluations that include cognitive testing both without and with the drug methylphenidate. The study also involves the use of other medications such as fluoxetine and risperidone to assess their effects. These treatments are being studied to observe their impact on psychiatric and cognitive symptoms in the syndromes mentioned. During the study, participants will have psychological assessments and molecular tests over a two-year period. Researchers will measure responsiveness to medical treatments and track changes in cognitive and psychiatric phenotypes. The study is non-blinded and sponsored by The Chaim Sheba Medical Center. Participants can expect monitoring and follow-up assessments to understand treatment effects and underlying biological factors.

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome